NDA 020998 · Upjohn
Celebrex
Celecoxib · Oral · Nonsteroidal Anti-inflammatory Drug
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Dec 31, 1998
Approved uses
7
Original approval plus efficacy supplements
Registered trials
631
125 Phase 3, 38 recruiting
FAERS reports
132,410
93,029 serious, 12,748 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use [see Warnings and Precautions (5.1) ] . • CELEBREX is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1) ] . Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and...
What it is approved for
From the label in effect Nov 22, 2024.
CELEBREX is indicated CELEBREX is a nonsteroidal anti-inflammatory drug indicated for: • Osteoarthritis (OA) ( 1.1 ) • Rheumatoid Arthritis (RA) ( 1.2 ) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1.3 ) • Ankylosing Spondylitis (AS) ( 1.4 ) • Acute Pain (AP) ( 1.5 ) • Primary Dysmenorrhea (PD) ( 1.6 ) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA [see Clinical Studies (14.1) ] . 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA [see Clinical Studies (14.2) ] . 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] . 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS [see Clinical Studies (14.4) ] . 1.5 Acute Pain For the management of acute pain in adults [see Clinical Studies (14.5) ] . 1.6 Primary Dysmenorrhea For the management of primary dysmenorrhea [see Clinical Studies (14.5) ] .
Mechanism: Celecoxib has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of prostaglandin synthesis in vitro . Celecoxib concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 28, 2018 Supplement 50 · Efficacy LabelLetter
- Dec 31, 2008 Supplement 27 · Efficacy LabelLetter
- Dec 15, 2006 Supplement 21 · Efficacy · priority review Pediatric Medical ReviewPediatric Written RequestPediatric Amendment 1
- Jul 29, 2005 Supplement 18 · Efficacy LetterLabel
- Jun 7, 2002 Supplement 9 · Efficacy ReviewLabelLetter
- Oct 18, 2001 Supplement 10 · Efficacy LabelReviewLetter
- Dec 31, 1998 Original approval · Type 1 - New Molecular Entity · priority review ReviewOther Important Information from FDALabel
4 products under this application
- CELEBREX · CELECOXIB 50MG · CAPSULE, ORAL · Prescription · TE AB
- CELEBREX · CELECOXIB 200MG · CAPSULE, ORAL · Prescription · TE AB
- CELEBREX · CELECOXIB 400MG · CAPSULE, ORAL · Prescription · TE AB
- CELEBREX · CELECOXIB 100MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Celecoxib" as an intervention, any sponsor and status, largest first.
- Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00346216 · 24,081 participants · Start Oct 4, 2006 · Primary completion Apr 12, 2016
Drug: celecoxib; Ibuprofen and 1 more · For: Arthritis, Rheumatoid
Sites: Alabaster, Alabama; Bessemer, Alabama; Birmingham, Alabama · 1,066 sites in all
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)Pivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00373685 · 8,067 participants · Start Oct 2006 · Primary completion Nov 2010
Drug: Celecoxib; Any commercially available NSAID with the indication for osteoarthritis · For: Osteoarthritis
Sites: Abbeville, Alabama; Alexander City, Alabama; Bay Minette, Alabama · 777 sites in all
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With ArthritisPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00141102 · 4,484 participants · Start Oct 2005 · Primary completion May 2009
Drug: Celecoxib; Diclofenac + Omeprazole · For: Osteoarthritis; Arthritis, Rheumatoid
Sites: Genk, Belgium; Ghent, Belgium; Hasselt, Belgium · 194 sites in all
NovartisNovartis (NVS)
NCT00145301 · 3,036 participants · Start Sep 2004 · Primary completion Nov 2005
Drug: Lumiracoxib · For: Osteoarthritis
Sites: Nuremberg, Germany
- Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or KneePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528188 · 3,021 participants · Start Jul 21, 2015 · Primary completion Oct 5, 2018
Drug: NSAID; Tanezumab 2.5 mg and 1 more · For: Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 507 sites in all
- Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or HipPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT00809354 · 2,720 participants · Start Feb 12, 2009 · Primary completion Oct 28, 2010
Drug: NSAID; tanezumab and 5 more · For: Osteoarthritis; Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 333 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective18,274
- pain12,761
- arthralgia11,408
- fatigue10,286
- nausea9,975
- off label use8,305
- drug hypersensitivity8,032
- diarrhoea7,761
- headache7,645
- rheumatoid arthritis7,585
- myocardial infarction7,052
- rash6,675
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,673 |
| 2005 | 4,992 |
| 2006 | 4,651 |
| 2007 | 6,894 |
| 2008 | 2,482 |
| 2009 | 2,404 |
| 2010 | 6,011 |
| 2011 | 3,916 |
| 2012 | 5,869 |
| 2013 | 6,069 |
| 2014 | 6,647 |
| 2015 | 6,720 |
| 2016 | 6,777 |
| 2017 | 6,322 |
| 2018 | 6,844 |
| 2019 | 7,930 |
| 2020 | 8,497 |
| 2021 | 6,148 |
| 2022 | 6,500 |
| 2023 | 5,721 |
| 2024 | 6,578 |
| 2025 | 6,704 |
| 2026 | 4,058 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Celebrex (Celecoxib)
2024 spending
$13.8M
Beneficiaries
3,370
11,915 claims
Per beneficiary
$4,082
$14.39 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $27,322,326 |
| 2021 | $19,072,505 |
| 2022 | $17,364,534 |
| 2023 | $16,190,429 |
| 2024 | $13,756,065 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Nissen SE, Yeomans ND, Solomon DH, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- Rofecoxib for osteoarthritis.
Garner SE, Fidan DD, Frankish R, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Celecoxib for osteoarthritis.
Puljak L, Marin A, Vrdoljak D, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Systematic Review
- WITHDRAWN: Celecoxib for rheumatoid arthritis.
Garner SE, Fidan D, Frankish RR, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Obeid S, Libby P, Husni E, et al. · Eur Heart J Cardiovasc Pharmacother 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.
Hochberg MC, Martel-Pelletier J, Monfort J, et al. · Ann Rheum Dis 2016 · Clinical Trial, Phase IV, Multicenter Study
Sponsor: Upjohn
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.